T2DM, which accounts for 90% of all diabetes, is a heterogeneous and progressive disease with a variety of causative and potentiating factors. The hyperglycemia of T2DM is often inadequately controlled, hence the need for a wider selection of glucose-lowering treatments. Ace Therapeutics can provide researchers engaged in drugs development of T2DM with more efficient function analysis and overall therapy services.

Source from: t2dm oral hypoglycemic development